Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0I5DM
|
|||
Drug Name |
N-arylmethyl-N-phenyl cyclic urea derivative 1
|
|||
Synonyms |
PMID28270010-Compound-Figure25-1
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
GENZYME CORPORATION
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H20F3N5O2S
|
|||
Canonical SMILES |
CC1(C(=O)N(C(=O)N1CC2=CC(=NC=C2)NC3=CC=CC=N3)C4=CC=C(C=C4)SC(F)(F)F)C
|
|||
InChI |
1S/C23H20F3N5O2S/c1-22(2)20(32)31(16-6-8-17(9-7-16)34-23(24,25)26)21(33)30(22)14-15-10-12-28-19(13-15)29-18-5-3-4-11-27-18/h3-13H,14H2,1-2H3,(H,27,28,29)
|
|||
InChIKey |
CYMSBDAPHJQPRL-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tropomyosin-related kinase A (TrkA) | Target Info | Inhibitor | [1] |
Target's Patent Info | Tropomyosin-related kinase A (TrkA) | Target's Patent Info | [1] | |
KEGG Pathway | MAPK signaling pathway | |||
Endocytosis | ||||
Apoptosis | ||||
Neurotrophin signaling pathway | ||||
Inflammatory mediator regulation of TRP channels | ||||
Pathways in cancer | ||||
Transcriptional misregulation in cancer | ||||
Thyroid cancer | ||||
Central carbon metabolism in cancer | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | |||
Reactome | Frs2-mediated activation | |||
ARMS-mediated activation | ||||
NGF-independant TRKA activation | ||||
PI3K/AKT activation | ||||
WikiPathways | MAPK Signaling Pathway | |||
BDNF signaling pathway | ||||
Integrated Pancreatic Cancer Pathway | ||||
NGF signalling via TRKA from the plasma membrane |
References | Top | |||
---|---|---|---|---|
REF 1 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.